01 marzo 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: Clinical, Angiographic, and OCT outcomes of CREDIT-1

Geng Wang MD1, Zhongwei Sun MSc2, Quanmin Jin MD1, Kai Xu MD1, Yi Li MD1, Xiaozeng Wang MD1, Yingyan Ma MD1, Haiwei Liu MD1, Xin Zhao MD1, Bin Wang MD1, Jie Deng MD1, Shaoyi Guan MD1, Meiling Ge MD1, Xiaoyan Wang MD1, Bo Xu MBBS2 andYaling Han MD, FACC1,*

Background: Although the first biodegradable polymer drug-eluting stent (BP-DES), EXCEL, was launched nearly a decade ago, in-stent restenosis and stent thrombosis remain pertinent clinical problems in practice. A new cobalt-chromium BP-DES EXCEL II has been developed with the aim of improving stent safety and efficacy.

01 marzo 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Morphological characteristics of severe aortic stenosis in China: Imaging corelab observations from the first Chinese transcatheter aortic valve trial

Hasan Jilaihawi MD1,†, Yongjian Wu MD2,†, Yuejin Yang MD2, Liang Xu MSc3, Mao Chen MD4, Jianan Wang MD5, Xiangqing Kong MD6, Ruiyan Zhang MD7, Moyang Wang MD2, Bin Lv MD8, Wei Wang MD9, Bo Xu MBBS2, Raj R. Makkar MD1, Horst Sievert MD10 andRunlin Gao MD2,

Objectives: We sought to describe the morphological characteristics of aortic valve disease in a Chinese population presenting for transcatheter aortic valve replacement (TAVR).

01 marzo 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents—the PETITION study: A prospective, randomized, multicenter study

Qi Zhang MD1, Xiao Long Wang MD2, Min Lei Liao MD3, Jian Hu MD1, Zhen Kun Yang MD1, Feng Hua Ding MD1, Jian Sheng Zhang MD1, Run Du MD1, Tian Qi Zhu MD1, Wei Feng Shen MD, PhD1 andRui Yan Zhang MD1,*

Background and purpose: Patients are at risk of developing periprocedural myonecrosis after percutaneous coronary intervention (PCI). We investigated whether the use of the platelet glycoprotein (GP) IIb/IIIa receptor inhibitor tirofiban could reduce periprocedural myocardial infarction (PMI) in patients with stable coronary artery disease undergoing elective PCI with overlapping stent implantation for long lesions.

01 marzo 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. A novel design biodegradable stent for use in congenital heart disease: Mid-term results in rabbit descending aorta

Surendranath R. Veeram Reddy MD1,*, Tré R. Welch PhD2, Jian Wang MD, PhD2, James A. Richardson DVM, PhD3, Joseph M. Forbess MD2, Matthew Riegel DVM4 andAlan W. Nugent MBBS1

Objectives: This study evaluates the feasibility of delivery and deployment of low and medium molecular weight (LMW and MMW, respectively) double-opposing helical (DH) poly-l-lactic acid biodegradable stent (BDS) in rabbit descending aorta (DAO). Secondary objectives were to assess patency and inflammation of stented vessels at 9 months and to investigate safety following intentional embolization of stent fragments in DAO.

01 marzo 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Neo-annulus: A reference plane in a surgical heart valve to facilitate a valve-in-valve procedure

Vinayak Bapat*, Benjamin Adams, Rizwan Attia, Alia Noorani andMartyn Thomas

Objectives: To determine the level of the narrowest plane (neo-annulus) of a surgical heart valve (SHV), which could be used for sizing and securing a transcatheter heart valve (THV) during a valve-in-valve (VIV) procedure and define its relationship with the fluoroscopic markers of the SHV.

01 marzo 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. In vitro validation and comparison of different software packages or algorithms for coronary bifurcation analysis using calibrated phantoms: Implications for clinical practice and research of bifurcation stenting

Yuki Ishibashi MD, PhD1, Maik J. Grundeken MD2, Shimpei Nakatani MD1, Javaid Iqbal MRCP, PhD1, Marie-Angele Morel BSc3, Philippe Généreux MD, PhD4, Chrysafios Girasis MD1,5, Jolanda J. Wentzel PhD6, Hector M. Garcia-Garcia MD, PhD1, Yoshinobu Onuma MD, PhD1,3,* andPatrick W. Serruys MD, PhD7

Background: The accuracy and precision of quantitative coronary angiography (QCA) software dedicated for bifurcation lesions compared with conventional single-vessel analysis remains unknown. Furthermore, comparison of different bifurcation analysis algorithms has not been performed.

01 abril 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: A propensity-score-adjusted analysis from the multicenter REAL registry (REgistro Regionale AngiopLastiche Dell`Emilia-Romagna)

Luigi Vignali MD, PhD1,*, Francesco Saia MD, PhD2, Laura Maria Beatrice Belotti MSC3, Emilia Solinas MD, PhD1, Paolo Guastaroba MSC3, Andrea Rubboli MD, FESC4, Antonio Manari MD5, Roxana Mehran MD, FACC, FAHA6, Diego Ardissino MD1 andRossana De Palma MD3

Objectives: The aim of this study was to compare long-term clinical outcomes in patients treated with new-generation drug-eluting stent (DES) or early-generation DES in a real-world registry.

15 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation

Israel M. Barbash MD, Sa´ar Minha MD, Itsik Ben-Dor MD, Danny Dvir MD, Rebecca Torguson MPH, Muhammad Aly MD, Elizabeth Bond BS, Lowell F. Satler MD, Augusto D. Pichard MD and Ron Waksman MD*

Objectives: To assess the prevalence at baseline, postprocedural incidence, and clinical impact of atrial fibrillation (AF) on consecutive patients undergoing transcatheter aortic valve implantation (TAVI).

15 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Position of Edwards SAPIEN transcatheter valve in the aortic root in relation with the coronary ostia

Spyridon Katsanos MD, PhD1, Philippe Debonnaire MD1,2, Frank van der Kley MD1, Philippe van Rosendael MD1, Emer Joyce MD1, Michiel A. de Graaf Msc1, Martin J. Schalij MD, PhD1, Arthur J.H.A. Scholte MD, PhD1, Jeroen J. Bax MD, PhD1, Nina Ajmone Marsan MD, PhD1 andVictoria Delgado MD, PhD1,*

Objectives: To determine the implications of stable coverage of the coronary ostia by the Edwards SAPIEN valve frame in terms of myocardial ischemia and subsequent percutaneous coronary intervention (PCI), following transcatheter aortic valve implantation (TAVI).

15 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Comparison of acute elastic recoil between the SAPIEN-XT and SAPIEN valves in transfemoral–transcatheter aortic valve replacement

Aatish Garg MD1,†, Akhil Parashar MD1,†, Shikhar Agarwal MD, MPH2, Olcay Aksoy MD2, Muhammad Hammadah MD1, Kanhaiya Lal Poddar MD2, Rishi Puri MD2, Lars G. Svensson MD, PhD3, Amar Krishnaswamy MD2, E. Murat Tuzcu MD, FACC2 andSamir R. Kapadia MD, FACC2,*

Background: The SAPIEN-XT is a newer generation balloon-expandable valve created of cobalt chromium frame, as opposed to the stainless steel frame used in the older generation SAPIEN valve. We sought to determine if there was difference in acute recoil between the two valves.

15 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Clinical impact of paravalvular leaks on biomarkers and survival after transcatheter aortic valve implantation

Dimitry Schewel MD1, Christian Frerker MD1, Jury Schewel MD1, Peter Wohlmuth PhD2, Felix Meincke MD1, Thomas Thielsen MD1, Felix Kreidel MD1, Karl-Heinz Kuck MD1 andUlrich Schäfer MD1,*

Background: There is accumulating evidence that up to 20% of the implanted devices after TAVI are associated with a significant degree of paravalvular leaks, which appear to be associated with a negative clinical outcome.

15 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. First generation versus new generation drug-eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: The Milan and New-Tokyo (MITO) registry

Toru Naganuma MD1,2,3, Alaide Chieffo MD1, Kensuke Takagi MD3, Vasileios F. Panoulas MD1,2,4, Satoru Mitomo MD3, Alessandro Sticchi MD1, Azeem Latib MD1,2, Tadashi Miyazaki MD1,2, Katsumasa Sato MD1,2, Charis Costopoulos MD1,2, Yusuke Fujino MD3, Matteo Montorfano MD1, Mauro Carlino MD1, Sunao Nakamura MD3 andAntonio Colombo MD1,2,*

Objectives: To compare the clinical outcomes following unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) of ostial/midshaft lesions between first and new generation drug-eluting stents (DES).

15 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Efficacy and safety of novel multi-lumen catheter for chronic total occlusions

Yoshiaki Mitsutake MD1, Adrian Ebner MD2, Alan C. Yeung MD1, Mark D. Taber MD3, Charles J. Davidson MD4 andFumiaki Ikeno MD1,*

Objective: To report our initial animal and human experience with a new multi-lumen catheter called MultiCross™ (Roxwood Medical, Inc.) in a porcine coronary model and patients with a chronic total occlusion (CTO).

15 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial

K. Gert van Houwelingen MD1,†, Hanim Sen MD1, Ming Kai Lam MD1, Kenneth Tandjung MD, PhD1, Marije M. Löwik PhD1, Frits H.A.F. de Man MD, PhD1, J. (Hans) W. Louwerenburg MD1, Martin G. Stoel MD, PhD1, Marc Hartmann MD, PhD1, Gerard C.M. Linssen MD, PhD2, Carine J. Doggen PhD3 andClemens von Birgelen MD, PhD, FSCAI1,3,*

Objective: To compare long-term outcome of patients treated for chronic total occlusion (CTO) lesions versus patients treated for non-CTO lesions only.

01 marzo 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: Insights from 2-year follow-up of the TWENTE trial

Ming Kai Lam MD1, Hanim Sen MD1, Kenneth Tandjung MD1, Marije M. Löwik PhD1, Mounir W.Z. Basalus MD, PhD1, Janne C. Mewes MSc2, Martin G. Stoel MD, PhD1, K. Gert van Houwelingen MD1, Gerard C.M. Linssen MD, PhD3, Maarten J. Ijzerman PhD2, Carine J.M. Doggen PhD2 andClemens von Birgelen MD, PhD, FSCAI1,2,*

Objectives: The aim of the present study was to assess the impact on clinical outcome of right coronary artery (RCA) ostial coverage with second-generation drug-eluting stents (DES).